Myeloid-specific CAMKK2 deficiency protects against diet-induced obesity and insulin resistance by rewiring metabolic gene expression and enhancing energy expenditure
Our data establish CAMKK2 as an important regulator of macrophage function and putative therapeutic target for treating obesity and related metabolic disorders.
Authors
- Surafel Tegegne (ORCID: https://orcid.org/0000-0002-3280-9117)
- Christopher R. M. Asquith (ORCID: https://orcid.org/0000-0001-5871-3458)
- Brittany Stork
- Mark A. Febbraio (ORCID: https://orcid.org/0000-0002-9296-4418)
- Brian York
- Kévin Nay
- Adam Dean
- Cristian Coarfa (ORCID: https://orcid.org/0000-0002-4183-4939)
- John W. Scott (ORCID: https://orcid.org/0000-0002-1896-9798)
- Sean M. Hartig (ORCID: https://orcid.org/0000-0002-2695-2072)
- Daniel E. Frigo (ORCID: https://orcid.org/0000-0002-0713-471X)
- Andrea R. Ortiz
- Anthony R. Means (ORCID: https://orcid.org/0000-0002-9207-6752)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Eastern Finland (FI)
- Baylor College of Medicine (US)
- Discovery Institute (US)
- St Vincents Institute of Medical Research (AU)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1016/j.molmet.2025.102250
- Citations
- 1
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.35